HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsUpgradesPrice Target
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.